Introduction Background
Expanding access to treatment is at the heart of new treatment targets for 2020 that aimed to end the AIDS epidemic as a public health danger by 2030. The 90-90-90 target is a plan which includes 90% of the people living with HIV to know their HIV status, 90% of the people who know their HIV status to receive ART and 90% of the people receiving ART to have suppressed viral loads. 1 The goal of treatment with antiretroviral drugs is to inhibit viral replication while minimizing toxicities and side effects associated with the available drugs. 2 The inhibition of virus HAART has resulted in substantial reductions in HIVassociated morbidity and mortality. 4, 5 changing an HIV diagnosis into a manageable chronic infection in Ethiopia even though there is a regional variation in the extent of its benefit. HAART also promoted growth, prolonged survival and improved the quality of life of all HIV-infected patients. 2 Studies from a different region of Ethiopia found that HAART can sustain virological efficacy for a substantial length of time and enhance immunological recovery irrespective of age. 6, 7 Despite the scale-up of ART, early mortality is a major challenge. A systematic review from Ethiopia found that 5-40.8% of the patients died during the follow-up period.
More than half (50-68.8%) of the deaths occurred within 6 months of initiating ART. 8 Most HIV-infected patients' complications can be improved within a few months after the initiation of HAART. 9 One of those complications that can be reversed by HAART is immunological deficiencies associated with untreated HIV infection. 2 Even if most patients on HAART can eventually attain an optimal CD4+ T-cell count outcome shortly after initiation, some may fail to achieve this result, and some of them achieve only after many years of HAART. 10 Some studies observed that one-third of successfully treated patients appear not to reach a normal CD4+ T-cell count within five years 11 and low CD4+ T-cell count for a longer period may increase the risk of complication. 12 Studies in Ethiopia observed immunologic failure to be the most common complication among HAART experienced patients. 13 Patients with low CD4+ T-cell at baseline have the highest risk of failure to achieve an optimal immunological recovery. The effectiveness of ART treatment will be dependent on different factors such as baseline CD4+, nutritional status, and adherence. Even though some studies in Ethiopia address the immunological none response rate and CD4 recovery, 7, 14 to the best of our knowledge, there are no studies from the study area concerning rates of CD4 + T-cells recovery and rates of immunological non-response to ART among HIV-infected patients. Therefore, we conducted a retrospective study to assess the trends of CD4 cell recovery among HIV patients after the initiation of antiretroviral therapy in Negelle, southeastern Ethiopia.
Methods and Materials Study Area and Design
This was a retrospective cross-sectional study conducted among HAART experienced HIV/AIDS patients at Arsi
Negelle health center during the year January 01, 2014-January 06, 2019. Arsi Negelle is located in the West Arsi zone, southeastern Ethiopia.
Data Collection
Data of 195 HAART experienced study participants who have uninterrupted every six months CD4+ T-cell count on their record were collected during the year January 1, 2014-January 06, 2019 using a pretested structured questionnaire. A baseline, 6-monthly CD4 + T-cells count, patients' sex, age, weight, WHO clinical stage and other basic information was collected from medical records. We retrieved the absolute CD4+ T-cell count which is the number of CD4+ Tcells/µL. Those records which missed a single every six month CD4+ T-cell result were excluded.
Statistical Analysis
All Data were pulled out from the patients' medical records and then recorded to data retrieval form, and then entered into Epidata 3.4 software for clean-up. Data were entered and analyzed using statistical package for social sciences (SPSS) for Windows version 20. Categorical variables were summarized as frequencies and percentages while numerical variables with non-normal distribution were summarized as median and IQR. Changes in CD4 + T-cells count every six months were also examined and stratified based on baseline CD4 + T-cells count. Finally, the result was presented using tables, bar graphs, and line graphs. Linear regression analysis was used to identify predictors of CD4 count change. A P-value of less than 0.05 was considered statistically significant.
Data Quality Assurance
The training was given to data collectors on how to review registration logbooks and maintain the confidentiality of the data. ART nurses working in the ART clinics were recruited as data collectors. Data quality was assured by collecting data with appropriate care and by applying the double-entry method. In addition to this, the quality of data was achieved by crosschecking of data collected. Data collection forms were examined for completeness, consistency, coding errors, accuracy, and clarity and missing values, by investigators before they were entered.
Results

Socio-Demographic and Clinical Characteristics
From a total of 195 study participants, 122 (62.6%) were female and the majority (34.4%) of the study participants are in the age group of 15-30 years with a median (IQR) age of 30 (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) years. Around 21.5% of the study participants are children of less than 15 years. 73.3% of the participants are either who did not take formal education or, are attending primary school (Table 1) . During this study, 31.3% and 8.2% of the study participants are under the WHO clinical stage I and IV, respectively. Regarding the baseline CD4+ T-cell count, the median CD4+ T-cell count was 257 (171-413, IQR) cells/uL. 36.4% had CD4+ T-cell count <50cells/µL, 30.8% had 51-200 cells/µL and 15.4% had 351-500cells/uL. None of them had a baseline CD4+ T-cell count of >500 cells (Table 1) .
Additionally, 6.2% of patients had been infected with TB before starting HAART and the majority (59%) of them are on Tenofovir (TDF)+ Lamivudine (3TC)+ Efavirenz (EFV) which are a standard first-line HAART regimen.
A Change in CD4+ T-Cell Count After Six-Month Treatment
From the total study participants of age less than 15 years, 23 (54.8%) of them had a CD4+ T-cell count change of >500 cell count after 6-month of treatment. 31.3%, 21.5% and 33.3% of the study participants of the age group of 15-30, 31-45 and above 45, respectively, had a CD4+ T change of greater than 500 cell count and the difference in change in CD4+ T-cell count after 6 months of treatment among different age groups was statistically significant (P=0.03) ( Table 2) .
12.2% male and 19.8% female participants had a change in CD4+ T count of less than 200 cell count at 6-month treatment, and 31.1% male and 34.7% female had a CD4+ T count of greater than 500 cell change from the baseline (Table 2) , though the distribution was not statistically significant (P=0.2). 47.5% of stage I study participants had a change in CD4+ T count of greater than 500cells after a 6-month treatment (Table 2) .
From those study participants with less than 50 cells at baseline, 40.8% of them still had a CD4+ T count change of fewer than 200 cells, and only 8.5% of them did achieve greater than 500 cells ( Table 2) . The difference in a change in CD4+ T count after 6 months of treatment based on the baseline CD4+ T count was statistically significant (P<0.001). Figure 1 shows the median 60 months CD4+ T-cell count increase. Along with HAART duration, CD4+ T count continually increased, even long after HAART initiation. The median of CD4+ T increased from 257cells/uL at the baseline to 382cells/uL after 6-month treatment, then to 591cells/uL after 60 months of treatment.
Trends of Median CD4+ T-Cell Count Recovery of the Study Participants
The sixty months of change in the median CD4+ T-cell count after the commencement of HAART is plotted in Figure 2 . After 6 months of HAART initiation, 16.9%, 25.6% and 65% of them remained less than 200 cells/uL, between 200-350 and >500 cells/uL, respectively. After 60 months of follow up, these percentages were improved to 0.5%, 5.6%, and 75.4%, respectively. The greatest CD4+ T count rise was seen after 6 months of treatment where 65% of the study participants reached a CD4+ T level of >500 cells/uL ( Figure 2 ). 
Median CD4+ T Count of Children of <15 Years Old
Immunological Non-Response Rate of Study Participants
The immunological non-response rate was defined as an increase of <50 cells/uL after HAART treatment. 14 The immunological non-response rate of the study participants is shown in Figure 3 . The percentages of patients who failed to attain an absolute CD4+ T-cell count increase of at least 50cells/uL at 12 months was 22.1%. This percentage drops to 13.8% after 36 and 42 months on treatment, and 7.2% after 54 months and 60 months of treatment ( Figure 4 ).
Non-Response Rate of the Study
Participants of Age ≥15 Years Old Figure 5 indicates the non-response rate of the study participants' age ≥15 years old. The immunological nonresponse rate decreased continuously from 6 months of treatment to the 60 months. The rate was very high during 6 months after HAART initiation (26.7%), continue to decrease to 17% after 1 year HAART treatment, then to 9.7% after 3years, hitting the lowest none-response rate during the 54th and the 60th month of treatment with 4.1% ( Figure 5 ). The mean non-response rate of study participants of age greater than 15 years old was 12.2%. The non-response rate of children of less than 15 years hits its highest rate after 1 year of treatment (23.8%), decreasing to 14.3% for the 48th, 54th and 60th consecutive month of CD4+ T measurements ( Figure 6 ). The mean non-response rate of children of less than 15 years was 16.93%.
Contribution of Children of Less Than 15 Years None-Response Rate to the Total Immunological Non-Response Rate
From a total of 22.1% immunological non -responsiveness after 12 months of HAART treatment, only 5.1% of it was because of children of less than 15 years old. The highest contribution of children to the total immunological nonresponsiveness was after 60 months of HAART treatment, which is 3.1% out of 7.2% of the total non-response rate ( Figure 7 ).
Factors Associated with a Change in CD4 + T-Cell Count
To assess factors associated with a change in CD4+ T-cell at the 60 th month from the baseline we used linear regression, and variables such as age, sex, baseline CD4+ T-cell count, baseline the WHO stage, TB infection, and ART regimen are inserted. Only baseline CD4+ T-cell was associated with a change in CD4+ T-cell count after 60 months of follow-up (Table 3) .
Discussion
HAART has been shown to improve the quality of life of HIV-infected patients by increasing the CD4+ T-cell lymphocyte count and by reducing viral load to undetectable levels. This leads to a remarkable reduction in AIDSrelated morbidity and mortality rates. This was a retrospective study carried out to assess CD4+ T-cell recovery, none-response rate and factor associated with a change in CD4+ T-cell count among HAART experienced HIV-positive patients at Arsi Negelle health center. Majorities (62.6%) of the study participants are female; a reflection of a fact that women under the sub-Saharan region are at increased risk for HIV/AIDS than males. The majority (19.8% Vs 12.2%) of females had a CD4+ T-cell change of less than 200 cells than males after 6 months of treatment. This implies an increased immunological non-responsiveness among female patients which is supported by another study 7, 15 though some studies will not support this. 16, 17 84.6% of the study participants had a CD4+ of <350cells/uL before HAART initiation. Although the median CD4 count at the time of HAART initiation is increasing, it remains significantly lower than 350cells/uL in almost all settings, including high-income countries. 18, 19 Improvements in overall CD4+ T-cell count among the patients were seen over time until 60 months of followup. This finding is supported by other retrospective longitudinal study conducted in eastern Ethiopia 20 and another a seven-year randomized control trial. 21 Our study population showed no major CD4 + T-cells increase beyond the first year of treatment. This could be because of poor response among patients with low CD4 counts, and possibly poor thymic function. 22 The greatest increment of CD4+ T-cell count lift seen after 6 months could be because of a quick drop in viral load following the inhibition of viral replication in productively infected cells during the first 2 weeks of HAART. This drop is associated with an increase in the CD4+ T-cell lymphocyte count. 23, 24 This finding was also in line with other studies. 14, 21 The median of CD4+ T-cell at baseline was 257cells/uL which was higher than a baseline median of the study done in Hawassa university referral hospital (167cells/uL). 14 The difference could be explained by the fact that our study included all participants of the age group. A high proportion of patients exhibited immunologic nonresponse (22.1%) after 12 months of treatment, a proportion similar to that observed in a study conducted in Northern Ethiopia (22.7%) 7 but higher than the study done in Hawassa, southern Ethiopia (19.3%). 14 These results confirm that even though HAART permits the reconstitution of the immune system, all HAART experienced may not achieve a significant gain of CD4+ T-cell counts. 16, 23 This could be explained by the fact that opportunistic infections and/or immune reconstitution inflammatory syndrome (IRIS) may develop, as well as early adverse drug reactions, such as drug hypersensitivity, especially in the first 3 months of ART. 25 From the present study, a CD4+ T-cell change was associated with a baseline CD4+ T-cell count (P≤0.001) which is in line with the study done in Gonder 26 and Hawassa but in contrast with a retrospective study done by reviewing 459 medical records which reported that the outcomes of HIV patients did not differ by baseline CD4+ T-cell count. 27 
Conclusion
From our study, we can conclude that HAART has helped the majority of the study participants to recover their CD4+ T-cell count; though some of the study participants are unable to recover their CD4+ T-cell count. The immunological non-response rate of study participants was 22.1% after 12 months on HAART and 7.2% at the end of the study.
Limitations of the Study
The retrospective study design limited our ability to gather data about factors that may influence the none-response rate. The small sample size was also another limitation of this study. 
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